MET and kidney cancer: To address the discrepancies between CCLE and CCLP data, we investigated mutations and CNAs in 24 key kidney cancer genes (TP53, VHL, PBRM1, SETD2, KDM5C, BAP1, NF2, PTEN, ARID1A, MICALCL, STAG2, SLC1A3, CDKN1A, MTOR, MET, SMARCB1, TCEB1, NFE2L2, PIK3CA, MLL3, FH, FLCN, TSC1 and TSC2) based on the three TCGA kidney cancer studies17, 22, 24 in detail (Fig. 3, also see Supplementary Table 3).